Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205

Benzinga Newsdesk www.benzinga.com Positive 78.6%

Neg 0% Neu 0% Pos 78.6%

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.